lanreotide (Autogel formulation)
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non Functioning Entero-pancreatic Endocrine Tumour
Conditions
Non Functioning Entero-pancreatic Endocrine Tumour
Trial Timeline
Feb 1, 2009 → Dec 1, 2015
NCT ID
NCT00842348About lanreotide (Autogel formulation)
lanreotide (Autogel formulation) is a phase 3 stage product being developed by Ipsen for Non Functioning Entero-pancreatic Endocrine Tumour. The current trial status is completed. This product is registered under clinical trial identifier NCT00842348. Target conditions include Non Functioning Entero-pancreatic Endocrine Tumour.
What happened to similar drugs?
1 of 1 similar drugs in Non Functioning Entero-pancreatic Endocrine Tumour were approved
Approved (1) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02365584 | Phase 2 | Terminated |
| NCT00891371 | Phase 2/3 | Completed |
| NCT00842348 | Phase 3 | Completed |
| NCT00681187 | Approved | Completed |
| NCT00517491 | Phase 2 | Withdrawn |
| NCT00326469 | Phase 2 | Completed |
| NCT00216398 | Approved | Completed |
| NCT00149188 | Approved | Completed |
| NCT00210457 | Phase 3 | Completed |
| NCT00234572 | Phase 2/3 | Completed |
Competing Products
2 competing products in Non Functioning Entero-pancreatic Endocrine Tumour
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Chromogranin A | Novartis | Approved | 39 |
| Pasireotide LAR | Novartis | Phase 2 | 35 |